Roxane Rohani, PharmD, MSc, BCACP

Cellular and Molecular Pharmacology Discipline

Center for Cancer Cell Biology, Immunology, and Infection

Dr. Roxane Rohani attained a Doctorate of Pharmacy degree from Tehran University of Medical Sciences, earned a Master of Science in Clinical Investigation degree at Northwestern University, and completed her Infectious Diseases Pharmacotherapy Fellowship at Midwestern University’s College of Pharmacy. Dr. Rohani’s research interest during her fellowship involved pharmacokinetic-pharmacodynamic modeling and simulation of antimicrobials to optimize their clinical use and safety. As part of her fellowship, Dr. Rohani was clinically engaged in ambulatory care practice at Northwestern Medicine. Prior to her fellowship, she was a practicing pharmacist.

Dr. Rohani joined the faculty of the Chicago Medical School as an Adjunct Clinical Instructor in 2016. She became an Assistant Professor in the Cellular & Molecular Pharmacology discipline in 2022. In addition, Dr. Rohani is a Board Certified Ambulatory Care Pharmacist and a Clinical Pharmacist Practitioner at the Infectious Diseases Clinic in the Captain James A. Lovell Federal Health Care Center.

Research

Dr. Rohani’s research is focused on premature aging in persons with HIV. She is interested in studying the impact of pharmacological interventions on delaying the onset of HIV-associated comorbidities. That includes the effects of adjunctive treatments as well as antiretroviral therapies on lowering chronic inflammation and immune activation among persons living with HIV.

Publications

• Mercer KJ, Brizzi MB, Burhoe DN, Senn JM, Rohani R, Nowicki DN, Januszka JE, Wordlaw R, Durham SH. Expanding expedited partner therapy and HIV prophylaxis in the emergency department. Am J Health Syst Pharm. 2023 Dec 23. PMID: 38142223. doi: 10.1093/ajhp/zxad322. Epub ahead of print. 
• Rohani R, Yarnold PR, Scheetz MH, Neely MN, Kang M, Donnelly HK, Dedicatoria K, Nozick SH, Medernach RL, Hauser AR, Ozer EA, Diaz E, Misharin AV, Wunderink RG, Rhodes NJ. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment. Antimicrob Agents Chemother. 2023 Nov 17. PMID: 37975660. doi: 10.1128/aac.00727-23. Epub ahead of print
• Rohani R, Malakismail J, Njoku E. Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV. Curr HIV/AIDS Rep. 2023 Nov 2. PMID: 37917387. doi: 10.1007/s11904-023-00677-7. Epub ahead of print.
• Pais GM, Marianski S, Valdez K, Melicor RP, Liu J, Rohani R, Chang J, Tong SYC, Davis JS, Scheetz MH. Flucloxacillin worsens while imipenem-cilastatin protects against vancomycin-induced kidney injury in a translational rat model. Br J Pharmacol. 2023 Sep 11. PMID: 37696768. doi: 10.1111/bph.16234. Epub ahead of print.
• Rhodes NJ, Rohani R, Yarnold PR, Pawlowski AE, Malczynski M, Qi C, Sutton SH, Zembower TR, Wunderink RG. Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0102322. PMID: 36472425. doi: 10.1128/aac.01023-22.
• Rohani R, Scheetz MH, Donnelly HK, Donayre A, Kang M, Diaz E, Dedicatoria K, Hauser AR, Ozer EA, Nozick S, Qi C, Pawlowski AE, Neely MN, Misharin AV, Wunderink RG, Rhodes NJ; NU SCRIPT Study investigators. Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia. J Antimicrob Chemother. 2022 Oct 28;77(11):2956-2959. PMID: 35869779. doi: 10.1093/jac/dkac245.  
• Rohani R, Hoff B, Jain M, Philbrick A, Salama S, Cullina JF, Rhodes NJ. Defining the importance of age-related changes in drug clearance to optimizing aminoglycoside dosing regimens for adult patients with Cystic Fibrosis. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):199-209. PMID: 34882292. doi: 10.1007/s13318-021-00734-9.
• Avedissian SN*, Rohani R*, Bradley J, Le J, Rhodes NJ. Optimizing aminoglycoside dosing regimens for critically-ill pediatric patients with augmented renal clearance: a convergence of parametric and non-parametric population approaches. Antimicrob Agents Chemother. 2021 Mar 18; 65(4): e.02629-20. PMID: 3352648. doi: 10.1128/AAC.02629-20.
  (* Contributed Equally)
• Khalili H**, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. Curr Clin Pharmacol. 2012 May 1; 7(2): 111-5. PMID: 22432842. doi: 10.2174/157488412800228910.
  (**Senior Author)